Myrta W. Atiles, MS
Amgen Manufacturing Ltd
Executive Director of Process Development
Myrta Atiles joined Amgen in 2003. She is currently the Executive Director of Process Development leading the collaboration with Eli Lilly on the manufacture of Etesevimab for the treatment of Covid-19. Prior this role she was the Executive Director of Drug Product Process Development in Puerto Rico’s facility including end to end from Formulation and Filling to Final Package Product.
Over her time at Amgen she has held several positions of increasing responsibility including Global Operations Lead for oncology programs, Process Development Director responsible to support the Oral Dosage and Fill & finish operations and Senior Scientist for Drug Substance in Amgen’s facility located in Puerto Rico. Her scope included Technology Transfer for New Product Introductions, Commercial Support, Productivity Capital Projects, Cleaning and Process Validation. She was responsible to transfer over 15 legacy and new products to a brand-new fill and finish facility and pioneered the platform standardization for the filling technology at the Amgen network and implementation of Artificial Intelligence for automatic inspection. Over the years, Myrta have led over 50 programs to the site from Drug Substance to Drug Product including facility start-ups and implementation of new technology.
Myrta also served as the president of the Amgen’s woman diversity group called WE2 from 2017-2018 where she created a program that promotes, networking, professional development and community service and is a member of the Puerto Rico Manufacturing Association woman chapter.
Prior to joining Amgen in 2003, Myrta held several Research and Development Scientist positions at Cellular Genomics (CT) and at Third Wave Technologies (WI) where for the latter, in addition to be a research scientist, she partnered with marketing as part of the company Road Show Strategy across several countries.
Myrta has a bachelor’s degree in Industrial Microbiology from the University of Puerto Rico, Mayagüez, and a master’s degree in Bacteriology and Molecular Biology from the University of Wisconsin, Madison.
Over her time at Amgen she has held several positions of increasing responsibility including Global Operations Lead for oncology programs, Process Development Director responsible to support the Oral Dosage and Fill & finish operations and Senior Scientist for Drug Substance in Amgen’s facility located in Puerto Rico. Her scope included Technology Transfer for New Product Introductions, Commercial Support, Productivity Capital Projects, Cleaning and Process Validation. She was responsible to transfer over 15 legacy and new products to a brand-new fill and finish facility and pioneered the platform standardization for the filling technology at the Amgen network and implementation of Artificial Intelligence for automatic inspection. Over the years, Myrta have led over 50 programs to the site from Drug Substance to Drug Product including facility start-ups and implementation of new technology.
Myrta also served as the president of the Amgen’s woman diversity group called WE2 from 2017-2018 where she created a program that promotes, networking, professional development and community service and is a member of the Puerto Rico Manufacturing Association woman chapter.
Prior to joining Amgen in 2003, Myrta held several Research and Development Scientist positions at Cellular Genomics (CT) and at Third Wave Technologies (WI) where for the latter, in addition to be a research scientist, she partnered with marketing as part of the company Road Show Strategy across several countries.
Myrta has a bachelor’s degree in Industrial Microbiology from the University of Puerto Rico, Mayagüez, and a master’s degree in Bacteriology and Molecular Biology from the University of Wisconsin, Madison.